FORA Capital’s Legend Biotech LEGN Stock Holding History

FORA Capital’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,284	Closed	-$269K	–	574
2022 Q1	$269K	Buy	+7,284	New	+$288K	0.05%	414

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

FORA Capital's LEGN Position: Q2 2022 in Review

FORA Capital sold out of Legend Biotech (LEGN) in Q2 2022, closing a stake of 7,284 shares — an estimated $269K sold.

FORA Capital first reported a position in LEGN in Q1 2022 and held it in 1 quarter. The position peaked at $269K in Q1 2022. 150 funds tracked by Wall St. Rank hold LEGN as of Q2 2022.

FORA Capital reported no remaining Legend Biotech position as of Q2 2022 after selling out during the quarter.
FORA Capital sold 7,284 Legend Biotech shares in Q2 2022, an estimated $269K.
FORA Capital first reported a position in Legend Biotech in Q1 2022 and held it in 1 quarter.
FORA Capital's Legend Biotech position peaked at $269K in Q1 2022.
150 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2022.

Based on FORA Capital's 13F filing for Q2 2022, filed 11 Aug 2022.